...
首页> 外文期刊>Molecular medicine. >Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis
【24h】

Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis

机译:通过共表达网络和药物 - 靶相互作用分析鉴定常见慢性肺病中的生物标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF) are three serious pulmonary diseases that contain common and unique characteristics. Therefore, the identification of biomarkers that differentiate these diseases is of importance for preventing misdiagnosis. In this regard, the present study aimed to identify the disorders at the early stages, based on lung transcriptomics data and drug-target interactions. To this end, the differentially expressed genes were found in each disease. Then, WGCNA was utilized to find specific and consensus gene modules among the three diseases. Finally, the disease-disease similarity was analyzed, followed by determining candidate drug-target interactions. The results confirmed that the asthma lung transcriptome was more similar to COPD than IPF. In addition, the biomarkers were found in each disease and thus were proposed for further clinical validations. These genes included RBM42, STX5, and TRIM41 in asthma, CYP27A1, GM2A, LGALS9, SPI1, and NLRC4 in COPD, ATF3, PPP1R15A, ZFP36, SOCS3, NAMPT, and GADD45B in IPF, LRRC48 and CETN2 in asthma-COPD, COL15A1, GIMAP6, and JAM2 in asthma-IPF and LMO7, TSPAN13, LAMA3, and ANXA3 in COPD-IPF. Finally, analyzing drug-target networks suggested anti-inflammatory candidate drugs for treating the above mentioned diseases. In general, the results revealed the unique and common biomarkers among three chronic lung diseases. Eventually, some drugs were suggested for treatment purposes.
机译:哮喘,慢性阻塞性肺病(COPD)和特发性肺纤维化(IPF)是三种严重的肺病,含有常见和独特的特性。因此,鉴定鉴定这些疾病的生物标志物对预防误诊具有重要性。在这方面,本研究旨在根据肺转录组织数据和药物 - 靶标相互作用鉴定早期阶段的疾病。为此,在每种疾病中发现差异表达的基因。然后,使用WGCNA在三种疾病中寻找特异性和共识基因模块。最后,分析了疾病相似性,然后确定候选药物 - 靶靶相互作用。结果证实,哮喘肺转录组比IPF更类似于COPD。此外,在每种疾病中发现生物标志物,因此提出了进一步的临床验证。这些基因包括在IPF,ATF3,PPP1R15A,ZFP36,SOCS3,Nampt和IPF,LRRC48和CETN2中的COPD,ATF3,PPP1R15A,ZFP36,SOCS3,Nampt和GADD45B中的哮喘,CYP27A1,GM2A,LGALS9,SPI1和NLRC4中的RBM42,STX5和TRIM41。在哮喘 - COPD,COL15A1中, Gimap6和Athma-IPF和LMO7,TSPAN13,Lama3和ANXA3中的JAM2在COPD-IPF中。最后,分析药物 - 目标网络建议抗炎候选药物治疗上述疾病。一般来说,结果揭示了三种慢性肺病中独特和常见的生物标志物。最终,有些药物建议用于治疗目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号